Fate Therapeutics Inc.

05/05/2021 | Press release | Distributed by Public on 05/05/2021 14:02

New Data from FT516 Phase 1 Study in Relapsed / Refractory Lymphoma to be Presented at 2021 American Society of Clinical Oncology Annual Meeting